MSB 3.21% $1.13 mesoblast limited

Ann: Remestemcel-L Improves Survival in High-Risk Acute GvHD, page-92

  1. 3,951 Posts.
    lightbulb Created with Sketch. 1352
    Good news is that it's been more than 6 months so not long now. One meeting. As for more trials, BS. FDA have confirmed that we can resubmit after agreement.
    They would not have agreed to this if they still required more trials.
    Recap for holders and those that are looking on

    https://hotcopper.com.au/data/attachments/3699/3699938-136bdb99e03779350687633712cc89dd.jpg


    https://hotcopper.com.au/data/attachments/3699/3699943-f2b944b2d16a93ed0851193c9f185e01.jpg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.